Menu
The 2019 Q2 biotech and pharmaceutical transactions were defined by an active IPO summer market as deal value increased across all categories when compared to …
Background An established, biomedical research facility was looking to enter into an agreement with a hospital organization which would absorb the research institute in exchange …
Background A pharmaceutical company, in the midst of a Phase III clinical trial, was considering a variety of strategic and financing alternatives as it prepared …
The 2019 Q1 biotech and pharmaceutical transactions have come to end, and the initial results showcase some stark differences when compared to the first quarter …
Biotechnology companies face unique challenges when it comes to understanding the value of their assets. During the early stages of development, an extraordinary level of …
Biotech and Life Sciences: Q3 2019 Summary
The 2019 Q3 biotech and pharmaceutical transactions were defined by an active M&A market as deal value increased across all categories when compared to the …